This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FSTX F-star Therapeutics (FSTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About F-star Therapeutics Stock (NASDAQ:FSTX) Get F-star Therapeutics alerts:Sign Up Key Stats Today's Range$7.12▼$7.1250-Day Range$4.42▼$7.1252-Week Range$2.07▼$7.12VolumeN/AAverage Volume709,213 shsMarket Capitalization$156.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. Read More Receive FSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FSTX Stock News HeadlinesAstria Therapeutics price target raised to $28 from $26 at OppenheimerNovember 14, 2024 | markets.businessinsider.comLake Street Remains a Buy on Aquestive Therapeutics (AQST)October 25, 2024 | markets.businessinsider.comBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's preparing for a "mind blowing" new launch that could see Tesla move away from electric cars... and into a new market. | Altimetry (Ad)Starton Therapeutics Announces Successful Feasibility Demonstration of STAR-LLD Using BD Evolve™ On-Body InjectorSeptember 18, 2024 | markets.businessinsider.comBicara Therapeutics Rises 39% in Debut on NasdaqSeptember 15, 2024 | marketwatch.comAnalysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX) and SAGE Therapeutics (SAGE)July 25, 2024 | markets.businessinsider.comBuy Rating for Astria Therapeutics: Promising STAR-0215 Outpaces Competitors with Strategic Trials and Market PotentialMay 10, 2024 | markets.businessinsider.comAstria Therapeutics: Strong Buy Rating on Robust Finances and Promising Clinical TrialsMay 10, 2024 | markets.businessinsider.comSee More Headlines FSTX Stock Analysis - Frequently Asked Questions How were F-star Therapeutics' earnings last quarter? F-star Therapeutics, Inc. (NASDAQ:FSTX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.06. The business had revenue of $0.75 million for the quarter, compared to analyst estimates of $7.18 million. What other stocks do shareholders of F-star Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that F-star Therapeutics investors own include New Age Brands (NF), Aurora Cannabis (ACB), Trican Well Service (TCW), Meta Platforms (META), NIO (NIO), Plug Power (PLUG) and Copper Mountain Mining (CMMC). Company Calendar Last Earnings11/10/2021Today10/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FSTX CIK1566373 Webwww.f-star.com Phone441223497400Fax508-381-0347Employees84Year Founded2006Profitability EPS (Trailing Twelve Months)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.28 million Net MarginsN/A Pretax Margin-213.97% Return on Equity-57.08% Return on Assets-42.40% Debt Debt-to-Equity Ratio0.15 Current Ratio3.38 Quick Ratio3.38 Sales & Book Value Annual Sales$21.17 million Price / Sales7.39 Cash FlowN/A Price / Cash FlowN/A Book Value$4.70 per share Price / Book1.51Miscellaneous Outstanding Shares21,980,000Free Float21,279,000Market Cap$156.50 million OptionableNot Optionable Beta0.85 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:FSTX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding F-star Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share F-star Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
